CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.